Inhibition of alfentanil metabolism by erythromycin

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Clinical pharmacology and therapy

• Publication date

  1989-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/clpt.1989.112PMID 2501060
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delayed respiratory depression after alfentanil.

  1988cited by this paper
• Evaluating the Accuracy of Using Population Pharmacokinetic Data to Predict Plasma Concentrations of Alfentanil

  1988cited by this paper
• Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients.

  1987cited by this paper
• Comparison of infusions of alfentanil or pethidine for sedation of ventilated patients on the ITU.

  1986cited by this paper
• Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man

  1983cited by this paper
• The Pharmacokinetics of Alfentanil (R39209): A New Opioid Analgesic

  1982cited by this paper
• Alfentanil--a kinetically predictable narcotic analgesic.

  1982cited by this paper
• NONUNIFORMITY OF ALFENTANIL PHARMACOKINETICS IN HEALTHY ADULTS

  1982cited by this paper
• Effect of erythromycin base on theophylline kinetics

  1981cited by this paper
• Depression of theophylline metabolism and elimination by troleandomycin and erythromycin.

  1981cited by this paper
• Effect of erythromycin on theophylline kinetics.

  1981cited by this paper
• Self-induction by erythromycin of its own transformation into a metabolite forming an inactive complex with reduced cytochrome P-450.

  1981cited by this paper
• Pharmacokinetics of Erythromycin in man.

  1978cited by this paper
• Demethylation of erythromycins by rabbit tissues in vitro.

  1965cited by this paper

• QM/MM Insights into Mechanism-Based Inactivation of Human CYP3A4: Formation of a Nitrosoalkane Intermediate from Erythromycin

  2025cites this paper
• Mechanism-based inactivation of cytochromes P450: implications in drug interactions and pharmacotherapy

  2024cites this paper
• Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

  2021cites this paper
• In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice

  2021cites this paper
• A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions

  2021cites this paper
• Effectiveness and safety of medicines used in COPD patients

  2020cites this paper
• Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice

  2020influential citation
• Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients

  2019cites this paper
• Drug Interactions in Anesthesia

  2017cites this paper
• Clinically Significant Interactions with Anesthetic Agents

  2016cites this paper
• Opioid Receptor Agonists and Antagonists

  2016cites this paper
• Irreversible enzyme inhibition kinetics and drug-drug interactions.

  2014cites this paper
• Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin

  2013influential citation
• Détermination et optimisation du contenu gastrique en anesthésie

  2013cites this paper
• Macrolides and Ketolides

  2012cites this paper
• Mechanism-based inhibition of CYP2C8 by gemfibrozil in humans : characterisation of time and dose relationships

  2011cites this paper
• Characterization of Cytochrome P450 Mechanism-Based Inhibition

  2010cites this paper
• Cytochrome P450-mediated drug interactions affecting lidocaine

  2009cites this paper
• Application of mechanism-based CYP inhibition for predicting drug–drug interactions

  2009cites this paper
• Pharmacogenetics of analgesics: toward the individualization of prescription.

  2008cites this paper
• Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.

  2008cites this paper
• Clinical Manual of Drug Interaction Principles for Medical Practice

  2008cites this paper
• Effect of the Treatment Period With Erythromycin on Cytochrome P450 3A Activity in Humans

  2007cites this paper
• A new compound-specific pleiotropic effect of statins: modification of plasma gamma-tocopherol levels.

  2007cites this paper
• Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half‐life

  2006cites this paper
• Individualizing analgesic prescription Part I: pharmacogenetics of opioid analgesics.

  2006cites this paper
• Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4

  2005cites this paper
• Effect of Tadalafil on Cytochrome P450 3A4–mediated Clearance: Studies in Vitro and in Vivo

  2005cites this paper
• British Journal of Anaesthesia Comparison of Incremental Spinal Anaesthesia Using a 32- Gauge Catheter with Extradural Anaesthesia for Elective

  2005cites this paper
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cites this paper
• Enzyme kinetics for clinically relevant CYP inhibition.

  2005cites this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cites this paper
• Einsatz der Opioide bei alten Patienten - Pharmakokinetische und pharmakodynamische Überlegungen

  2004cites this paper
• A retrospective review of the use of alfentanil in a hospital palliative care setting

  2004cites this paper
• Scientific, Mechanistic and Regulatory Issues with Pharmacokinetic Drug-Drug Interactions

  2004cites this paper
• Clinical outcomes and management of mechanism-based inhibition of cytochrome P 450 3 A 4

  2004cites this paper
• [Use of opioids in the elderly -- pharmacokinetic and pharmacodynamic considerations].

  2004cites this paper
• ffect of tadalafil on cytochrome P 450 A 4 – mediated clearance : Studies in vitro nd in vivo

  2004cites this paper
• Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment.

  2003cites this paper
• Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil

  2003cites this paper
• Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin

  2003cites this paper
• [Cytochrome P450 enzymes and their role in drug interactions].

  2002cites this paper
• Cytochrom-P450-Enzyme und ihre Bedeutung für Medikamenteninteraktionen

  2002cites this paper
• Zentral wirksame Analgetika vom Typ Opioid

  2001cites this paper
• Mechanism-Based Inhibition of Human Cytochromes P450: In Vitro Kinetics and In Vitro—In Vivo Correlations

  2001cites this paper
• Pharmacokinetic Aspects of Treating Infections in the Intensive Care Unit

  2001cites this paper
• An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.

  2000cites this paper
• In vivo drug‐drug interaction studies‐ A survey of all new molecular entities approved from 1987 to 1997

  2000cites this paper
• Metabolite-intermediate complexation and inhibition of microsomal CYP3A in rat liver by diltiazem

  2000cites this paper
• THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*

  2000cites this paper
• Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

  2000cites this paper
• Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series.

  1999cites this paper
• Adverse drug interactions in dental practice: interactions associated with analgesics, Part III in a series.

  1999cites this paper
• Drug interactions during anesthesia. General principles.

  1999cites this paper
• Recent advances and developments in the clinical use of i.v. opioids during the peroperative period.

  1998cites this paper
• 4 The role of the cytochrome P450 system in drug interactions in anaesthesia

  1998cites this paper
• The Effect of Intravenous and Oral Fluconazole on the Pharmacokinetics and Pharmacodynamics of Intravenous Alfentanil

  1998cites this paper
• IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP 3 A

  1998cites this paper
• Opioid Drug-Drug Interactions: A Review

  1998cites this paper
• In vitro and in vivo drug interactions involving human CYP3A.

  1998cites this paper
• Safety Considerations in the Use of Drug Combinations During General Anaesthesia

  1997cites this paper
• Adverse drug interactions in anesthesia.

  1997cites this paper
• Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions.

  1997cites this paper
• Lidocaine Toxicity with Tumescent Liposuction: A Case Report of Probable Drug Interactions

  1997cites this paper
• Chapter 5 – Drug Interactions with Antimicrobial Agents

  1997cites this paper
• The Systemic Inflammatory Response to Cardiopulmonary Bypass: Pathophysiological, Therapeutic, and Pharmacological Considerations

  1997cites this paper
• Identification of Cytochrome P450 3A1/2 as the Major P450 Isoform Responsible for the Metabolism of Fentanyl by Rat Liver Microsomes

  1996cites this paper
• Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting

  1996cites this paper
• Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.

  1996cites this paper
• Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N‐demethylation

  1996cites this paper
• Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation

  1996cites this paper
• Inhibition of microsomal cytochromes P450 in rat liver by the tricyclic antidepressant drug desipramine and its primary oxidized metabolites.

  1996cites this paper
• Pharmacologie des morphiniques et des antagonistes de la morphine

  1995cites this paper
• Pharmacokinetic drug interactions. Part 1: Drugs A-C.

  1995cites this paper
• Drug interactions with intravenous and local anaesthetics

  1994cites this paper
• Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation

  1994cites this paper
• Human Alfentanil Metabolism by Cytochrome P450 3A3/4. An Explanation for the Interindividual Variability in Alfentanil Clearance?

  1993cites this paper
• Interactions of preoperative erythromycin administration with general anaesthesia

  1993cites this paper
• Sufentanil Disposition: Is It Affected by Erythromycin Administration?

  1993cites this paper
• Drug Interactions of Clinical Significance with Opioid Analgesics

  1993cites this paper
• Pharmacokinetic Drug Interactions with Antimicrobial Agents

  1993cites this paper
• Analgesie durch Opioide in der Pädiatrie

  1992cites this paper
• P450 Enzymes

  1992cites this paper
• Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.

  1992cites this paper
• [Analgesia with opioids in the paediatric patient.].

  1992cites this paper
• Interaktionen von Anästhetika und anderen Pharmaka

  1992cites this paper
• Pharmacokinetic Drug Interactions of Macrolides

  1992cites this paper
• Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants.

  1992cites this paper
• Pharmacokinetics of opioid agonists and antagonists

  1991cites this paper
• Midazolam and erythromycin.

  1991cites this paper
• Pharmacokinetic drug interactions in anaesthetic practice.

  1991cites this paper
• Recent advances in pediatric infectious diseases and their impact on dermatology.

  1991cites this paper
• Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism.

  1991cites this paper
• Pharmacokinetic and pharmacodynamic principles

  1991cites this paper
• Pharmacokinetic Drug Interactions in Anaesthetic Practice

  1991cites this paper
• Influence of Age on the Pharmacokinetics of Alfentanil

  1990cites this paper
• Prolonged alfentanil effect following erythromycin administration.

  1990cites this paper
• Influence of age on the pharmacokinetics of alfentanil. Gender dependence.

  1990cites this paper
• Variables of patient‐controlled analgesia. 3: test of an infusion‐demand system using alfentanil

  1990cites this paper
• Alfentanil clearance is independent of the polymorphic debrisoquin hydroxylase.

  1988cites this paper